Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease Including Assessment of Quality of Life

NCT00501046 is registered in ClinicalTrials.gov with Tanabe Pharma Corporation as lead sponsor.

NCT NCT00501046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00501046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease Including Assessment of Quality of Life
Lead sponsor
Tanabe Pharma Corporation
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2007
Completion date
October 31, 2011
Enrollment
1,015 (actual)
Sites
106

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease